

Synthesis and Pharmacology of Seleninic Acid Analogues of the Inhibitory Neurotransmitter γ -Aminobutyric Acid


Nicolai Stuhr-Hansen,[†] Bjarke Ebert,[§] Povl Krogsgaard-Larsen,[‡] and Jan Kehler^{*†}

Department of Chemistry, University of Copenhagen, 5 Universitetsparken, DK-2100, Denmark, and Departments of Medicinal Chemistry and Pharmacology, The Royal Danish School of Pharmacy, 2 Universitetsparken, DK-2100, Denmark

jke@lundbeck.com

Received September 27, 1999

ABSTRACT



The first seleninic acid analogues of γ -aminobutyric acid (GABA) and of the specific GABA_A agonist piperidine-4-carboxylic acid (isonipecotic acid), **1** and **2**, respectively, have been synthesized and shown to be potent agonists at the GABA receptors.

The concept of bioisosteric replacement continues to play an important role in bioorganic and medicinal chemistry in the design of novel pharmacological tools as well as new therapeutic agents with optimal pharmacological profile and improved pharmacokinetic properties.¹ A number of acidic groups have been shown to be useful carboxyl group bioisosteres, although different biological systems frequently show markedly different bioisosteric tolerance. The 3-isoxazolol group has been successfully used in the synthesis of analogues of the central inhibitory neurotransmitter γ -aminobutyric acid (GABA).² Recently the phosphinic acid³ and the sulfinic acid⁴ groups have been explored in the preparation of bioisosteres of GABA. However, the bioisosteric potential of the seleninic acid group has, so far, not been investigated, although it has structural and protolytic proper-

ties similar to those of the carboxyl group. 2-Aminoethaneseleninic acid has previously been synthesized,⁵ and we now report the synthesis and in vitro pharmacology of the seleninic acid analogues of GABA and of the specific GABA_A agonist piperidine-4-carboxylic acid (isonipecotic acid), **1** and **2**, respectively.

Of the four organic acids of selenium (selenol and selenenic, seleninic, and selenonic acids), the seleninic acid group is the most stable. Seleninic acids can be prepared in several ways, e.g., by hydrolysis of trihalogeno alkylselenanes,⁶ oxidative hydrolysis of selenocyanates,⁷ and controlled

* Present address: H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Copenhagen, Denmark.

[†] University of Copenhagen.

[‡] Department of Medicinal Chemistry.

[§] Department of Pharmacology.

(1) (a) Cannon, J. G. In *Burger's Medicinal Chemistry and Drug Discovery*; Wolff, M. E., Ed.; 1995; 5th ed., Vol. 1, p 783. (b) Thornber, C. W. *Chem. Soc. Rev.* **1979**, 8, 563.

(2) Krogsgaard-Larsen, P.; Froelund, B.; Jørgensen, F. S.; Schousboe, A. *J. Med. Chem.* **1994**, 37, 2489. (b) Krogsgaard-Larsen, P.; Froelund, B.; Kristiansen, U.; Frydenvang, K.; Ebert, B. *Eur. J. Pharm. Sci.* **1997**, 5, 355.

(3) (a) Froestl, W.; Mickel, J. S.; Sprecher, von G.; Diel, P. J.; Hall, R. G.; Maier, L.; Strub, D.; Melillo, V.; Baumann, P. A.; Bernasconi, R.; Gentsch, C.; Hauser, K.; Jaekel, J.; Karlsson, G.; Klebs, K.; Maitre, L.; Marescaux, C.; Pozza, M. F.; Schmutz, M.; Steinmann, M. W.; Riesen, van H.; Vassout, A.; Mondadori, C.; Olpe, H.-R.; Waldmeier, P. C.; Bittiger, H. *J. Med. Chem.* **1995**, 38, 3313. (b) Kehler, J.; Ebert, B.; Dahl, O.; Krogsgaard-Larsen, P. *J. Chem. Soc., Perkin Trans. 1* **1998**, 3243. (c) Murata, Y.; Woodward, R. M.; Miledi, R.; Overman, L. E. *Bioorg. Med. Chem. Lett.* **1996**, 6, 2073.

(4) Shue, H.-J.; Chen, S.; Blythin, D. J.; Carruthers, N. I.; Spitler, J. M.; Wong, S.-C.; Chapman, R. W.; Rizzo, C.; West, R.; She, H. S. *Bioorg. Med. Chem. Lett.* **1996**, 6, 1709; **1998**, 8, 3059.

(5) (a) Pichat, L.; Thiers, H. M. *Tetrahedron* **1961**, 12, 1. (b) Reich, H. J.; Willis, W. W.; Wollowitz, S. *Tetrahedron Lett.* **1982**, 23, 3319.

(6) Backer, H. J.; Winter, H. J. *Recl. Trav. Chim. Pays-Bas.* **1937**, 56, 492 and ref 5a.

(7) Morgan, G. T.; Burstall, F. H. *J. Chem. Soc.* **1930**, 1497.

Scheme 1. Syntheses of Amino Seleninic Acids **1** and **2**




Table 1. GABA_A and GABA_B Receptor Effects of the Dihydrosylate Salts of **1** and **2**

compd	binding at rat GABA _A receptors (IC ₅₀ , μM) ^a	binding at rat GABA _B receptors (IC ₅₀ , mM) ^a	potency at human GABA _A receptors (EC ₅₀ , μM) ^b	maximum response at human GABA _A receptors (% relative to maximum GABA)
GABA	0.128	0.025	15	100
1	2.0	0.08	350	30
isonipecotic acid	0.33 ¹⁴	> 1000	400	60
2	4.0	> 100	200	3

^a In vitro inhibition of GABA receptor binding in rat brain synaptosomes using a previously described method.¹⁵ ^b Activities at human GABA_A receptors expressed in *Xenopus* oocytes using the method previously described.¹⁶

oxidation of selenols,⁸ but are most frequently and readily prepared by oxidative cleavage of organodiselenides by aqueous HNO₃,⁹ aqueous H₂O₂,¹⁰ aqueous Br₂,¹¹ or ozone.¹² Our approach was to utilize a method for the ready and reliable generation of a sodium polyselenide **3** solution in DMSO (Scheme 1),¹³ which reacts with Boc-protected 3-bromopropylamine **4a** or Boc-protected 4-bromopiperidine **4b** to give bis(3-*N*-*tert*-butoxycarbonylaminopropyl)diselenide **5a** and bis(*N*-*tert*-butoxycarbonyl-4-piperidyl)diselenide **5b**, respectively. The diselenides **5a** and **5b** were extracted from the reaction mixture with ether upon dilution with water. Although the diselenides could also be synthesized without amino protecting group, the resulting bis-aminoalkyl diselenides were not easily purified. After removal of the Boc groups of **5a** and **5b** by treatment with *p*-toluenesulfonic acid in hot acetic acid, followed by dilution of the reaction mixture with dichloromethane, the seleninic acids were prepared by gentle oxidation of the diselenides

with 35% aqueous H₂O₂ at room temperature. This procedure caused the dihydrosylate salts of **1** and **2** to precipitate from the reaction mixture as colorless crystalline salts, which were purified by recrystallization from water–acetic acid. Notably, both compounds were shelf-stable for several months. Bicarbonate solutions of **1** and **2** were stable for weeks at room temperature.^{19,20} The preparation and isolation of **1** was relatively straightforward, as compared with the procedures described for several alkane-1-seleninic acids, including 2-aminoethaneseleninic acid. The finding that **2** could be isolated as a stable material is quite remarkable, since, to the best of our knowledge, this is the first example of a compound with a seleninic acid situated at a secondary carbon atom.

The affinity for the GABA_A and GABA_B receptors of the dihydrosylate salts of **1** and **2** as well as their functional (agonist/antagonist) properties were characterized in binding studies, guinea pig ileum, and cloned GABA_A receptors (Table 1). It has been experimentally established, that there is a high correlation between binding data obtained in cell lines expressing human GABA receptors¹⁷ and rat brain homogenates,¹⁸ reflecting that the inter species homology in GABA_A receptor sequence and structure is very high. The 3-aminopropaneseleninic acid **1** was shown to be a potent and relatively selective GABA_B agonist. At cloned human GABA_A receptors **1** was a medium potent partial agonist with a maximum response of 30% relative to GABA. In contrast, the piperidine-4-seleninic acid **2** was shown to be a potent and selective partial GABA_A agonist with a

(8) Shaw, E. H.; Reid, E. E. *J. Am. Chem. Soc.* **1926**, *48*, 520.
 (9) (a) Painter, Franke; Gortner. *J. Org. Chem.* **1940**, *5*, 587. (b) Backer, H. J.; van Dam. *Recl. Trav. Chim. Pays-Bas.* **1935**, *54*, 532.
 (10) (a) House, K. L.; Dunlap, R. B.; Odom, J. D.; Wu, Z.-P.; Hilvert, D. *J. Am. Chem. Soc.* **1992**, *114*, 8573. (b) Kloc, K.; Mlochowski, J.; Syper, L. *Liebigs Ann. Chem.* **1989**, 811 and ref 5.
 (11) Pichat, L.; Thiers, H. M. *Tetrahedron* **1961**, *12*, 1.
 (12) Reich, H. J.; Hoeger, C. A.; Willis, W. W. *Tetrahedron* **1985**, *41*, 4771.
 (13) (a) Eggert, H.; Nielsen, O.; Henriksen, L. *J. Am. Chem. Soc.* **1986**, *108*, 1725. (b) Klayman, D. L. *J. Org. Chem.* **1965**, *30*, 2454.
 (14) Krosggaard-Larsen, P.; Johnston, G. A. R.; Lodge, D.; Curtis, D. R. *Nature* **1977**, *268*, 53.
 (15) Kristiansen, U.; Hedegaard, A.; Herdeis, C.; Lund, T. M.; Nielsen, B.; Hansen, J. J.; Falch, E.; Hjed, H.; Krosggaard-Larsen, P. *J. Neurochem.* **1992**, *58*, 1150.
 (16) Ebert, B.; Wafford, K. A.; Whiting, P. J.; Krosggaard-Larsen, P.; Kemp, J. A. *Mol. Pharm.* **1994**, *46*, 957.

(17) Ebert, B.; et al. *Mol. Pharm.* **1997**, *52*, 1150 and ref 16.
 (18) Krosggaard-Larsen; et al. *J. Med. Chem.* **1985**, *28*, 1612.

maximum response of 3% of that of GABA. Quite surprising, whereas the seleninic acid analogue **1** of GABA activates the GABA_A receptor with a potency 20 times lower than that of GABA, the seleninic acid analogue **2** is differing in

(19) **3-Aminopropaneseleninic Acid Dihydrotosylate (1)**. A solution of sodium tetraselenide was prepared in the following manner: To a stirred solution of sodium methoxide (3.38 g, 63 mmol) and 95% aqueous hydrazine (0.5 g, 16 mmol) in DMSO (80 mL) was added selenium (9.87 g, 125 mmol) in small portions during a 5 min period under vigorous stirring. The reaction mixture was further stirred at room temperature for 30 min under nitrogen. Di-*tert*-butyl dicarbonate (10.9 g, 50 mmol) and 3-bromopropylamine hydrobromide (10.9 g, 50 mmol) in triethylamine-THF (1:4, 125 mL) was stirred for 4 h at room temperature. The reaction mixture containing **4a** was filtered directly into the sodium tetraselenide solution. The resulting black reaction mixture was stirred at room temperature under nitrogen for 2 h, diluted with water (400 mL), and extracted with ether (3 × 125 mL). The combined ether phases were washed with water (2 × 50 mL), dried (Na₂SO₄), filtered, and evaporated in vacuo to give the crude diselenide **5a** as a yellow oil. *p*-Toluenesulfonic acid monohydrate (19.0 g, 0.1 mol) in glacial acetic acid (0.3 L) was added, and the resulting solution was heated (100 °C) for 30 min (to ensure complete removal of the Boc-group). After cooling to 0 °C in an ice bath dichloromethane (0.15 L) was added. The solution was dropwise titrated (yellow to colorless) with 35% aqueous hydrogen peroxide during a 10 min period. During the reaction the product was formed as a white precipitate, which was filtered off and dissolved in water-glacial acetic acid (1:9, 0.1 L) at 60 °C. Glacial acetic acid (0.1 L) was added and the flask left at room temperature overnight. Filtration and drying (vacuum oven, 45 °C) gave **1** (5.75 g, 22%) as white

potency by a factor of 2 as compared with isonipecotic acid but produces a maximum response of only 3% as compared to 60% for isonipecotic acid.

In conclusion, we have synthesized the first bioactive seleninic acid analogues **1** and **2**, of GABA and shown them to be potent GABA_B and GABA_A agonists, respectively.

OL991093W

flakes: mp 126–130 °C (dec). C₁₇H₂₅NO₈S₂Se: found C 39.71, H 4.66, N 2.70, S 12.43; calcd C 39.69, H 4.90, N 2.72, S 12.46. ¹H NMR (D₂O) δ: 1.91–1.95 (2 H, t, *J* = 7.7 Hz), 2.02 (6 H, s), 2.80–2.85 (4 H, m), 4.70 (5 H, s), 6.99 (4 H, d, *J* = 7.9 Hz), 7.41 (4 H, d) ppm. ⁷⁷Se NMR (D₂O) δ: 1224 ppm.

(20) **Piperidine-4-seleninic Acid Dihydrotosylate (2)**. The product was prepared from 4-bromopiperidine hydrobromide in analogy with the synthesis of 3-aminopropaneseleninic acid dihydrotosylate. Purification was achieved by dissolving the product in the minimum amount of water-glacial acetic acid (1:7) at 60 °C followed by addition of the same volume of glacial acetic acid. Upon cooling the precipitate was filtered off and dried (vacuum oven, 45 °C) to give **2** (15%) as white flakes: mp 162–164 °C (dec). C₁₉H₂₇NO₈S₂Se: found C 42.19, H 4.86, N 2.52, S 11.99; calcd C 42.22, H 5.03, N 2.59, S 11.86. ¹H NMR (D₂O) δ: 1.70–1.89 (2 H, m), 2.06–2.12 (2 H, m), 2.18 (6 H, s), 2.85–2.95 (2 H, m), 3.04–3.16 (1 H, m), 3.37–3.43 (2 H, m), 4.70 (4 H, br s), 7.15 (4 H, d, *J* = 8.0 Hz), 7.41 (4 H, d) ppm. ⁷⁷Se NMR (D₂O) δ: 1225 ppm.